| 1 |
|
| 2 |
<p align="left"><font size="4" color="#FF9933"><b><img src="t/development.gif" width="225" height="16"></b></font></p> |
| 3 |
<table width="90%" border="0" cellspacing="0" cellpadding="0" align="center"> |
| 4 |
<tr> |
| 5 |
<td height="10" width="19%"> |
| 6 |
<div align="center"><b>PROJECT</b></div> |
| 7 |
</td> |
| 8 |
<td height="10" width="26%"> |
| 9 |
<div align="center"><b>INDICATION</b></div> |
| 10 |
</td> |
| 11 |
<td height="10" width="24%"> |
| 12 |
<div align="center"><b>STATUS</b></div> |
| 13 |
</td> |
| 14 |
</tr> |
| 15 |
</table> |
| 16 |
<table width="90%" border="1" cellspacing="0" cellpadding="0" align="center"> |
| 17 |
<tr> |
| 18 |
<td width="19%"> |
| 19 |
<div align="center">PLD - 116</div> |
| 20 |
</td> |
| 21 |
<td width="26%"> |
| 22 |
<div align="center">Inflammatory Bowel Disease (IBD)</div> |
| 23 |
</td> |
| 24 |
<td width="24%"> |
| 25 |
<div align="center">Clinical Development</div> |
| 26 |
</td> |
| 27 |
</tr> |
| 28 |
<tr> |
| 29 |
<td width="19%"> |
| 30 |
<div align="center">PLD - 117</div> |
| 31 |
</td> |
| 32 |
<td width="26%"> |
| 33 |
<div align="center">Oncology<br> |
| 34 |
Hematology</div> |
| 35 |
</td> |
| 36 |
<td width="24%"> |
| 37 |
<div align="center">Clinical Development</div> |
| 38 |
</td> |
| 39 |
</tr> |
| 40 |
<tr> |
| 41 |
<td width="19%"> |
| 42 |
<div align="center">PLD - 118</div> |
| 43 |
</td> |
| 44 |
<td width="26%"> |
| 45 |
<div align="center">Anti-fungal</div> |
| 46 |
</td> |
| 47 |
<td width="24%"> |
| 48 |
<div align="center">Clinical Development</div> |
| 49 |
</td> |
| 50 |
</tr> |
| 51 |
<tr> |
| 52 |
<td width="19%"> |
| 53 |
<div align="center">PLR - 1</div> |
| 54 |
</td> |
| 55 |
<td width="26%"> |
| 56 |
<div align="center">Anti-infective</div> |
| 57 |
</td> |
| 58 |
<td width="24%"> |
| 59 |
<div align="center">Discovery</div> |
| 60 |
</td> |
| 61 |
</tr> |
| 62 |
<tr> |
| 63 |
<td width="19%"> |
| 64 |
<div align="center">PLR - 13</div> |
| 65 |
</td> |
| 66 |
<td width="26%"> |
| 67 |
<div align="center">Inflammation<br> |
| 68 |
Asthma</div> |
| 69 |
</td> |
| 70 |
<td width="24%"> |
| 71 |
<div align="center">Discovery</div> |
| 72 |
</td> |
| 73 |
</tr> |
| 74 |
<tr> |
| 75 |
<td width="19%"> |
| 76 |
<div align="center">PLR - 9</div> |
| 77 |
</td> |
| 78 |
<td width="26%"> |
| 79 |
<div align="center">Anti-infective</div> |
| 80 |
</td> |
| 81 |
<td width="24%"> |
| 82 |
<div align="center">Discovery</div> |
| 83 |
</td> |
| 84 |
</tr> |
| 85 |
<tr> |
| 86 |
<td width="19%"> |
| 87 |
<div align="center">PLR - 14</div> |
| 88 |
</td> |
| 89 |
<td width="26%"> |
| 90 |
<div align="center">Inflammation<br> |
| 91 |
RA, IBD</div> |
| 92 |
</td> |
| 93 |
<td width="24%"> |
| 94 |
<div align="center">Discovery</div> |
| 95 |
</td> |
| 96 |
</tr> |
| 97 |
</table> |
| 98 |
|
| 99 |
|
| 100 |
<p><b>PLD-116</b></p> |
| 101 |
<p>Approval of the German authorities was obtained to conduct the PLD-116 Phase |
| 102 |
I clinical study in Germany in December 2000. Prior to that, all the activities |
| 103 |
necessary to fulfill the requirements for the clinical testing of the compound |
| 104 |
had been undertaken and the pre-clinical testing completed. The PLD-116 project |
| 105 |
team has been established in December 1999, to develop peptide PL-10.1 into |
| 106 |
a drug for the treatment of inflammatory bowel disease. The peptide is derived |
| 107 |
from a natural protein and provides a novel anti-inflammatory treatment option |
| 108 |
for inflammatory bowel disease.</p> |
| 109 |
<p><b>PLD-117</b></p> |
| 110 |
<p>The peptide PLD-117 for the treatment of thrombocytopenia, a severe complication |
| 111 |
of cancer chemotherapy, was brought to clinical study trials in the USA in December |
| 112 |
2000. The proposed treatment is based on a unique approach using peptide that |
| 113 |
activates thrombopoietin (TPO) receptor. Prior to favourable communication from |
| 114 |
the FDA regarding the IND filling, and the evaluation of the clinical protocol, |
| 115 |
PLIVA has signed a licensing agreement with Receptron, Inc., a Californian based |
| 116 |
Biotech Company, and acquired exclusive rights to develop and market this possible |
| 117 |
new drug.</p> |
| 118 |
<p><b>PLD-118</b></p> |
| 119 |
<p>The licensed in novel antifungal agent PLD-118 was successfully brought into |
| 120 |
clinical development ahead of schedule in November 2000. PLD-118 has the potential |
| 121 |
to be the first novel oral antifungal for the treatment of Candida infections |
| 122 |
since the introduction of azoles in the 80's. After completing the preclinical |
| 123 |
package and successful review of necessary documents by the ethics committee |
| 124 |
in Germany, clinical studies started in November.</p> |
Parent Directory
| 
Revision Log